Articles scientifiques

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Auteurs : Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, OToole SA, Viale G, Van de Vijver K, de Wind R, Von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R
Année : 2016
Journal : Mod Pathol
Volume : 29(10)
Pages : 1155-64

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

Auteurs : Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P
Année : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(10)
Pages : 1792-801

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Auteurs : Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart-Gebhart M, Michiels S, Sotiriou C
Année : 2016
Journal : JAMA Oncol
Volume : 2(2)
Pages : 217-24

Twenty years of anti-HER2 therapy-associated cardiotoxicity.

Auteurs : Pondé NF, Lambertini M, de Azambuja E
Année : 2016
Journal : ESMO Open
Volume : 1
Pages : e000073

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Auteurs : Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC
Année : 2016
Journal : Anticancer Drugs
Volume : 27(4)
Pages : 342-8

Metastatic breast cancer: The Odyssey of personalization.

Auteurs : Sonnenblick A, Pondé N, Piccart-Gebhart M
Année : 2016
Journal : Mol oncol
Volume : 10(8)
Pages : 1147-59

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Auteurs : Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA
Année : 2016
Journal : JAMA Oncol
Volume : 2(12)
Pages : 1557-64

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Auteurs : Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y
Année : 2016
Journal : ESMO Open
Volume : 1
Pages : e000097

p53 Reactivation by PRIMA-1 Met (APR-246) sensitises V600E/K BRAF melanoma to vemurafenib.

Auteurs : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Sales F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G
Année : 2016
Journal : Eur J Cancer
Volume : 55
Pages : 98-110

Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.

Auteurs : Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, Piccart-Gebhart M, Zardavas D, Nagele E, Bjelic-Radisic V, Cardoso F, Sprangers MA, Velikova G, Bottomley A
Année : 2016
Journal : Lancet Oncol
Volume : 17
Pages : e294-304

Corrigendum to Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicenter prospective study" [J. Geriatr. Oncol. 6 (2015) 401-410]."

Auteurs : Baitar A, Kenis C, Moor R, Decoster L, Luce S, Bron D, Van Rijswijk R, Rasschaert M, Langenaeken C, Jerusalem G, Lobelle JP, Flamaing J, Milisen K, Wildiers H
Année : 2016
Journal : J Geriatr Oncol
Volume : 7
Pages : 142-143

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

Auteurs : Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, OConnor D, Oliver K, Piault-Louis E, Piccart-Gebhart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJ, Velikova G, Coens C
Année : 2016
Journal : Lancet Oncol
Volume : 17
Pages : e510-e514

Emerging Drugs Targeting Human Epidermal Growth Factor Receptor 2 (Her2) In The Treatment Of Breast Cancer.

Auteurs : Awada G, Gombos A, Aftimos P, Awada A
Année : 2016
Journal : Expert Opin Emerg Drugs
Volume : 21(1)
Pages : 91-101

Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy.

Auteurs : Latifyan S, Genot MT, Klastersky J
Année : 2016
Journal : Support Care Cancer
Volume : 24(9)
Pages : 3687-93

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Auteurs : Hortobagyi GN, Chen D, Piccart-Gebhart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J
Année : 2016
Journal : J Clin Oncol
Volume : 34(5)
Pages : 419-26

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.

Auteurs : Lambertini M, Pinto AC, Ameye L, Jongen L, Del Mastro L, Puglisi F, Poggio F, Bonotto M, Floris G, Van Asten K, Wildiers H, Neven P, de Azambuja E, Paesmans M, Azim HA Jr
Année : 2016
Journal : Br J Cancer
Volume : 115(12)
Pages : 1471-78

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Auteurs : Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Loi S, Smyth MJ
Année : 2016
Journal : Cancer Res
Volume : 76
Pages : 264-74

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Auteurs : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart-Gebhart M
Année : 2016
Journal : Ann Oncol
Volume : 27
Pages : 205-207

Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study.

Auteurs : Dhondt V, Goffin F, Roca L, Dresse D, Leroy C, Kerger J, Cordier L, de Forges H, Veys I, Liberale G
Année : 2016
Journal : Int J Gynecol Cancer
Volume : 26(5)
Pages : 912-7

Targeted adjuvant therapy in breast cancer.

Auteurs : Zardavas D, Tryfonidis K, Goulioti T, Piccart-Gebhart M
Année : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(12)
Pages : 1263-75